期刊文献+

盐酸拓扑替康联合顺铂治疗上皮性卵巢癌的临床研究 被引量:1

Efficacy and toxicity of topotecan hydrochloride plus cisplatin in treatment of epithelial ovarian cancer
原文传递
导出
摘要 目的探讨盐酸拓扑替康联合顺铂治疗上皮性卵巢癌的疗效及毒副反应。方法将手术后经病理检查确诊为Ⅱ~Ⅳ期上皮性卵巢癌的68例患者按入选时间顺序分为2组:治疗组与对照组,每组34例。治疗组给予顺铂90 mg/m2,静脉滴注,d1;盐酸拓扑替康0.8 mg/m2,d1~5。对照组给予顺铂90 mg/m2静脉滴注,d1;环磷酰胺800 mg/m2静脉注射,d1。2组患者均以20 d为1疗程。5~7个疗程后评价疗效。结果临床疗效:治疗组完全缓解10例,部分缓解16例,有效率为76.5%;对照组完全缓解5例,部分缓解14例,有效率为55.8%。治疗组与对照组有效率比较差异有统计学意义(P<0.05)。毒副反应:发生Ⅲ~Ⅳ度骨髓抑制的患者,治疗组16例(47.1%),对照组为13例(38.2%),2组毒副反应发生率差异无统计学意义(P>0.05)。结论盐酸拓扑替康联合顺铂是治疗上皮性卵巢癌的有效方案,临床疗效较好,安全性高,其不良反应可控制,患者可耐受。 Objective To study the therapeutic effects and adverse effects of topotecan hydrochloride plus cisplatin in treatment of epithelial ovarian cancer in order to a reference for choosing therapeutic regimen of epithelial ovarian cancer. Methods A total of 68 eligible patients with Ⅱ - IV stage epithelial ovarian cancer verified by pathology were enrolled in this study. The patients were divided into experimental group and control group ( n = 34 each) according to eligible time sequence. The patients in experimental group were treated with intravenous infusing topotecan hydrochloride ,0.8 mg/m2 every day for 5 days and intravenous infusing cisplatin 90 mg/m2 on the first day;The patients in Control group were treated with intravenous injecting cyclophosphamide,800 mg/m2 on the first day and intravenous infusing cisplatin 90 mg/m2 on the first day. The courses of two groups all were 20 days. After 5 - 7 courses, the therapeutic effects and adverse effects were evalua- ted. Results In the experimental group, complete remission (CR)was seen in 10 cases;partial remission(PR) was seen in 16 cases;the effective rate was 76.5%. In the control group, CR was seen in 5 cases;PR was seen in 14 cases; the effective rate was 55.8%. There was a significant difference in effective rate between the experimental group and the control group( P 〈 0.05 ). The common toxicity was grade Ⅲ - IV myelosuppression in two groups. There was no significant difference in toxicity between experimental group and control group (47.1% vs 38.2%, P 〉 0.05 ). Conclusions Topotecan hydrochloride plus cisplatin is an effective regimen for the treatment of epithelial ovarian cancer with a good therapeutic effects,high safety and tolerable adverse effects.
出处 《中国临床研究》 CAS 2012年第11期1044-1046,共3页 Chinese Journal of Clinical Research
关键词 盐酸拓扑替康 顺铂 上皮性卵巢癌 化疗 Topotecan hydrochloride Cisplatin Epithelial ovarian cancer Chemotherapy
  • 相关文献

参考文献8

  • 1Husseinzadeh N. Status of tumor markers in epithelial ovarian cancer has there been any progress? A review [ J]. Gynecol Oncol, 2011,120( 1 ) :152 - 157.
  • 2左建中,夏姿芳.19例年轻卵巢上皮性癌患者临床特点及预后分析[J].实用预防医学,2011,18(5):867-869. 被引量:3
  • 3燕鑫,陈春玲,张岩,廖秦平.61例复发性上皮性卵巢癌相关临床因素分析[J].中国妇产科临床杂志,2004,5(3):180-184. 被引量:4
  • 4成海燕,陈秀玮.紫杉醇脂质体与紫杉醇治疗100例卵巢癌分析[J].中国肿瘤,2008,17(8):723-725. 被引量:18
  • 5Romanelli S, Perego P, Pratesi G, et al. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems [ J ]. Cancer Chemother Pharmacol, 1998,41 (5) :385 - 390.
  • 6Chiara S, Tognoni A, Pastrone I, et al. Topotecan and ifosfamide as salvage treatment in advanced ovarian cancer [ J ]. Gynecol Oncol, 2004,93(2) :474 -478.
  • 7Safra T, Menczer J, Bemstein R, et al. Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer[J]. Gynecol Oncol,2007,105( 1 ) :205 -210.
  • 8Gronlund B, Hansen HH, Hogdall C, et al. Efficiency of low dose topotecan in second line treatment for patients with epithelial ovarian carcinoma[ J]. Cancer,2002,95 ( 8 ) : 1656 - 1662.

二级参考文献19

  • 1陈蓉,沈铿,吴鸣,潘凌亚,黄惠芳,杨佳欣,郎景和.30岁以下卵巢上皮性癌患者21例临床分析[J].中华妇产科杂志,2005,40(6):417-420. 被引量:7
  • 2曹泽毅,于莎莎.妇科恶性肿瘤治疗后一年内未控与复发原因的研究——附全国61所医院1753例分析[J].中华妇产科杂志,1996,31(7):417-421. 被引量:21
  • 3[1]Thigpen TJ, Vance RB, Khansur T. Second line chemotherapy forrecurrent carcinoma of the ovary. Cancer, 1993,71(Supp 14 ):1559-1564.
  • 4[3]Tentes AA,Tripsiannis G,Markakidis SK,et al. Peritoneal cancer index:a prognostic indicator of survival in advanced ovarian cancer. Eur J Surg Oncol,2003,29:69-73.
  • 5[5]Hoskins WJ,Mc Guire WP,Brady MF,et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol,1994,170:170-174.
  • 6[7]Kurtz JE, Deplanque G, Duclos B, et al. Paclitaxel-anthra cycline combination chemotherapy in relapsing advanced ovarian cancer after platinum-based chemotherapy:a pilot study. Gynecol Oncol, 1998, 70:414-417.
  • 7[8]Rubin SC, Hoskins WJ, Saigo PE, et al. Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy. Gynecol Oncol, 1991, 42: 137-141.
  • 8[9]Eisenkop SM, Friedman RL, Spirtos N. Secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian cancinoma. Cancer,2000, 88:144-153.
  • 9[11]Bolis G,Scarfone G,Tateo S,et al. Response and toxicity to topotecan in sensitive ovarian cancer cases with small residual disease after firstline treatment with carboplatium and paclitaxel. Gynecol Oncol,2001,80:13-15.
  • 10[12]Kapp KS, Kapp DS,Poschauko J, et al. The prognostic significance of peritoneal seeding and size of post surgical residual in patients with stage Ⅲ epithelial ovarian cancer treated with surgery,chemotherapy,and high dose radiotherapy. Gynecol Oncol,1999,74:400-407.

共引文献22

同被引文献5

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部